Pharma sector to log 9% revenue growth over next 3 years: Crisil

29 Dec 2017 Evaluate

Offsetting headwinds in exports and intensifying competition, Indian pharmaceutical industry is expected to witness better revenue growth in the near term with healthy cash flows, on the back of robust domestic demand and rising need for complex products in the West. Credit rating agency, Crisil in its latest report has said that the sector would log in a 9% revenue growth over the next three years ending 2020.

The rating agency however, said that the current fiscal year would be critical for the pharma sector overall export, as it will able to grow at rate of 1% only. It also pointed that over half of the exports are to the regulated markets in the West but those are set to de-grow by 5 per cent this fiscal, after growing 3 per cent last fiscal, due to greater price erosion in existing products amid rising competition and delayed launches of new products or import ban on existing products following scrutiny from the USFDA.

However, over the medium term, the ratings agency sees trend reversal with 7% annual growth in revenues of regulated markets and 6% annual growth in overall exports, on the back of faster product approvals from the FDA. As per report, research and development (R&D) spending of the companies are expected to increase 700 basis points over fiscal 2017 to reach 30% of annual revenue from the regulated markets over the medium term and better access to healthcare, higher penetration of health insurance and increasing lifestyle diseases will sustain domestic demand.


© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×